Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study.

ABSTRACT:

Background

Key goals in the treatment of CAP include early response to treatment and achievement of clinical stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials for the treatment of community-acquired bacterial pneumonia. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe Complicated Skin and Soft Tissue Infections [cSSTI] or CAP in the Hospital Setting) was a retrospective observational study, providing current data on the clinical management and resource burden of CAP in real-life settings in European hospitals. This analysis reviews the characteristics and outcomes of patients showing early positive response to treatment (time to clinical stability [TCS] ≤4 days, as as

SUBMITTER: Blasi F 

PROVIDER: S-EPMC3903813 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature